



INTELLOTRACKER

Small molecule oncotherapy

May 2023



ARANCA'S QUARTERLY SECTORIAL UPDATE ACROSS FOUR DIMENSIONS....





DEVELOPMENTS

Technology Updates		Boserolimab is under clinical development by Merck and currently in Phase II for non-small cell lung cancer. The drug candidate acts by targeting antigen CD27 and is administered by the intravenous route. Source: Pharmaceutical Technology
Technology Updates	 	AlphaFold has been used in an end-to-end AI-powered drug discovery platform (Pharma.AI) that includes a biocomputational engine (PandaOmics) and a generative chemistry platform (Chemistry42), to identify a new drug for a novel target for liver cancer treatment. Source: Chemical Science
Technology/Innovations		An MUSC Hollings Cancer Center research team has created small molecules designed to stimulate immune cells to fight cancer, inhibiting a specific enzyme that has not been targeted earlier with small molecules for cancer. Source: Institute Website
Technology/Innovations		Scientists from Institute of Cancer Research have revealed details of the discovery of new inhibitors of the BCL6 protein, which engage in driving several cancer types including the blood cancer B-cell lymphoma. Source: Institute Website
Technology/Innovations		Scientists at SRI International have developed and optimized a new peptide comprising two or more amino acids, to act as a delivery vehicle for drugs to treat non-small cell lung cancer. Source: Company Website



DYNAMICS

Marketing Campaign		Verastem Oncology has launched a fresh campaign called "Let's Talk about LGSOC" that features resources and management for a specific type of ovarian cancer known as low-grade serous ovarian cancer (LGSOC). Source: Fierce Pharma
--------------------	--	---



DRIVERS

Regulations/Approvals		U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to lead drug candidate of Qualigen Therapeutics, QN-302, for the indication of pancreatic cancer. QN-302 is a small molecule selective transcription inhibitor. Source: GlobeNewswire
Regulations/Approvals		U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to RRx-001, a direct NLRP3 inhibitor and Nrf2 upregulator with anti-inflammatory and antioxidant properties, for the prevention/attenuation of severe oral mucositis in chemotherapy. Source: Cision
Regulations/Approvals		HotSpot Therapeutics has announced the clearance by the U.S. Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for HST-1011, an investigational small molecule allosteric inhibitor of casitas B-lineage lymphoma-B (CBL-B). Source: Cision
Regulations/Approvals		FDA has granted orphan drug designation to BEA-17, a first-in-class LSD1 inhibitor, for the treatment of patients with glioblastoma (GBM). To date, there are no FDA-approved therapies that can target LSD1, and BEA-17 is not approved in any country. Source: Company Website



DIVERSIFICATION

Merger & Acquisitions	 	Pfizer and Seagen have entered into a definitive merger agreement under which Pfizer will acquire Seagen, for \$229 in cash per Seagen share for a total enterprise value of \$43 billion. Source: Company Website
Company Collaboration	 	Kronos Bio has entered a discovery collaboration in the field of oncology with Genentech, a member of the Roche Group, focused on discovering and developing small-molecule drugs that modulate transcription factor targets selected by Genentech. Source: Company Website
Company Collaboration	 	Covant Therapeutics has entered into an exclusive research collaboration and worldwide licensing agreement with Boehringer Ingelheim to develop a novel small molecule immunotherapy targeting Covant's ADAR1 for cancer patients. Source: GlobeNewswire
VC Investment		BiPER Therapeutics, a French preclinical biotechnology company developing first-in-class drug candidates targeting BiP protein to treat gastrointestinal cancers, has raised €1.25 million (\$1.35 million) in seed funding. Source: Labiotech
Licensing Activities VC Investment		Volastra Therapeutics, a clinical stage cancer biotechnology company has completed the in-licensing of Amgen's soviltresib (AMG650), an oral, first-in-class small molecule inhibitor of KIF18A. In parallel, the company has closed a \$60 million financing. Source: Company Website

SOLUTION PORTFOLIO – TECHNOLOGY RESEARCH & ADVISORY

IP Strategy	Technology Intelligence	Growth & Strategy
<p>How best can we proactively manage and monetise our technical knowhow / intellectual property?</p>	<p>How best can we keep abreast of technology trends, competitor activity and headwinds / tailwinds in our domain?</p>	<p>Which technologies do we invest in? How do we ensure quick wins? Speed to market?</p>
<ul style="list-style-type: none"> IP Portfolio Analysis 	<ul style="list-style-type: none"> Competitor Benchmarking 	<ul style="list-style-type: none"> R&D Strategy Roadmaps
<ul style="list-style-type: none"> IP Monetisation 	<ul style="list-style-type: none"> Tech / IP Landscapes 	<ul style="list-style-type: none"> Technology Scouting
<ul style="list-style-type: none"> IP Valuation 	<ul style="list-style-type: none"> Technology Watch 	<ul style="list-style-type: none"> Open Innovation
<ul style="list-style-type: none"> Prior Art Searches 	<ul style="list-style-type: none"> Market Analysis / Trends 	<ul style="list-style-type: none"> Product Development



GROWTH ADVISORY



INVESTMENT RESEARCH & ANALYTICS



VALUATION & FINANCIAL ADVISORY



TECHNOLOGY RESEARCH & ADVISORY



PROCUREMENT & SUPPLY CHAIN INTELLIGENCE

This material is exclusive property of Aranca. No part of this presentation may be used, shared, modified and/or disseminated without permission. All rights reserved.